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A B S T R A C T
The first part of this article will provide an overview of cervical cancer screening in the UK during the years before,
during and after the introduction of a highly successful centrally organised cervical screening programme in 1988: since
then the incidence of invasive cervical cancer has fallen by more than 40%. Screening was introduced in a background of
opportunistic screening with poor quality control during a period of time when risk of disease was increasing, which will
be demonstrated by national registrations of carcinoma in situ as well as invasive cancer. The programme is still facing
new challenges and has recently recorded falling screening coverage in younger women, the causes of which have yet to
be established. Liquid-based cytology is in the process of being rolled out nationally but high-risk human papillomavirus
testing has yet to be introduced into the National Health Service (NHS) programme. Lessons from our experience may be
relevant to countries introducing and maintaining organised programmes elsewhere under similar circumstances. The
second part of the article will consider laboratory quality control as practiced in the UK and as recommended in the sec-
ond edition of the European Guidelines for Quality Assurance in Cervical Cancer Screening. These evidence-based guide-
lines provide recommendations for organising and monitoring quality control as well as for introducing new technology
and standardising terminology, which are equally relevant for new and existing programmes. Invasive cancer audit may
highlight areas where procedures could be improved in any programme but also can also demonstrate the effectiveness of
screening.
Key words: Organised cervical screening, quality control, invasive cervical cancer incidence, carcinoma in situ, cer-
vical intraepithelial neoplasia, new technology
Introduction
Across Europe in 2002 there were approximately
60,000 new cases and 30,000 deaths from invasive cervi-
cal cancer with a 5-fold variation in those rates1. The
lowest were in countries such as the United Kingdom
(UK) with organised programmes, which can maximise
the positive and minimise the adverse effects, but there
are many different models of care. The aim is to reach
the population at risk and provide a high quality service
that takes account of specificity as well as sensitivity of
the test. Demographic differences and changes of risk
with time must also be considered when comparing pro-
grammes in countries as diverse as the whole of Europe.
Although rates of mortality and incidence relate to
screening coverage of the population at risk, no amount
of screening will be successful without good quality con-
trol. The second edition of the European Guidelines for
Quality Assurance in Cervical Cancer Screening provides
a comprehensive overview of cervical cancer control in
Europe and describes methodology for all aspects of quality
control1. These guidelines are equally relevant to exist-
ing and new programmes with respect to target popula-
tions, intervals for screening, evidence-based indications
for new technology, methodology for quality control, mo-
nitoring the effectiveness of screening and the impor-
tance of standardising terminology across a diverse and
increasingly mobile group of nations.
Cervical screening has been successful in the UK
since a centrally organised National Health Service Cer-
vical Screening Programme (NHSCSP) was introduced
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in 1988, which can be demonstrated by national registra-
tions of invasive and in situ carcinoma of the uterine cer-
vix (www.statistics.gov.uk). Registrations prior to 1992
can be obtained from the Office for National Statistics on
CD ROM2. The effects of changing risk of disease, screen-
ing coverage and quality control continue to influence
the evolution of the programme and may provide lessons
for other countries. The challenge of new technology af-
fects new and existing programmes alike and should be
introduced as and when it can be shown to improve sen-
sitivity or specificity of the test. The experience of intro-
ducing liquid-based cytology (LBC) to the NHSCSP will
be discussed as well as the role of high-risk human
papillomavirus (hrHPV) testing, which is yet to be intro-
duced nationally.
Screening in the UK Before and After
Organised Screening Was Introduced
During the 1970s and 1980s general practitioners
were paid a supplement to screen women aged 35–64, or
earlier for women with three or more children. A rela-
tively ineffective paper-based system of 5-yearly recall
was in place but most screening was opportunistic, ma-
inly in young women, and quality control was poor. Inci-
dence per 100,000 total female population remained al-
most steady at 15.0 to 16.0 throughout the 1970s and
1980s when UK rates were the highest in Europe. How-
ever, there was a striking change in the pattern of disease
during those decades3. Although overall numbers of can-
cers changed little during a 10-year period there was a
nearly 3-fold increase in rates of deaths, invasive can-
cers, registrations of carcinoma in situ and high-grade
cytological abnormalities in women born since the mid-
-1940s almost certainly because of the greater sexual
freedom allowed by the availability of reliable contra-
ception4. Screening coverage was poorly documented un-
til 1990 but was lower in older (over age 40) than youn-
ger women. National registrations of carcinoma in situ,
which include cervical intraepithelial neoplasia (CIN)
grade 3 since 1983, provide evidence that many young
women were effectively screened, albeit opportunisti-
cally: the number of registrations of carcinoma in situ
had already overtaken those of invasive cancer as early
as 1981 (Figure 1 and 2). Shortly before the introduction
of organised screening in 1988 incidence of invasive can-
cer had started to rise, reaching a maximum 17.4 in
1988: the age distribution reflects the increased risk in
younger women (Figure 3). It was recognised at the time
that quality control was poor5.
The organised programme aimed to improve all as-
pects of quality control as well as setting up a centralised
register to invite all eligible women aged 20–64 at least
every five years. Incidence fell steadily during the 1990s
to a figure fluctuating between 8.0 and 9.0 since 2001.
Mortality rates declined from 1988 in all birth cohorts
(from 1922) screened at least once in the new programme
but declined earlier in life for women first screened when
they were younger (the latest in the study were born in
1952) in whom the death rate was substantially lower
throughout life6. This evidence is supported by the obser-
vation that high-grade cervical intraepithelial neoplasia
(CIN) is predominantly treated in young women: more
than 80% of CIN3 was found in women aged less than 40
before, during and after the introduction of organised
screening (Figure 4). There has been some concern about
a recent decision in the UK no longer to invite women
aged 20–24 for screening7, which was based on results of
a national audit8 and is consistent with EU guidelines1.
However, a recent study in Iceland showed the benefit of
lowering the age limit to include women aged 20–249,
which is in accordance with recommendations in the
USA (www.ahrq.gov/clinic/3rduspstf/cervcan/cervcanrr).
The NHSCSP is facing a new challenge since a fall in
screening coverage has been recorded in young women,
particularly those aged 25–29 in whom the highest preva-
lence of CIN3 is recorded. The reasons for the fall in cover-
age have yet to be established but the evidence suggests a
need to encourage young women to be screened even
though there is debate about the age of the first invitation.
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Fig. 1. Registration of invasive and in situ carcinoma of the uterine
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Fig. 2. Registration of invasive and in situ carcinoma of the uterine
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Quality Control of all Aspects of
the Screening Programme
The European guidelines emphasise the importance
of quality control of all aspects of the screening pro-
gramme1. Invitations for screening should be clear but
informative, smear-takers should receive training and
should be able to explain the test results to women; labo-
ratories should have the infrastructure required for a
high-quality service in terms of accommodation, equip-
ment, adequate numbers and levels of non-medical and
clerical staff, availability of training and update, infor-
mation technology and medical supervision; colposcopy
clinics should similarly be equipped, staffed, trained, su-
pervised and monitored; and terminology should at least
be translatable into nationally recognised systems. The
NHSCSP also addresses all aspects of the programme,
providing evidence-based guidelines and monitoring per-
formance through regional quality assurance reference
centres (QARCs). A centralised computer-based register
of screening records is essential and ideally should in-
clude histology and colposcopy records and should be
linked to regional and national cancer incidence and
mortality registries.
Quality Control in the Laboratory
The mechanisms of laboratory quality control will be
considered with respect to the interlinked functions of
primary screening, final cytology reports and comparison
with outcome. At each level accuracy depends on the sub-
sequent as much as the previous step and the final out-
come itself depends on the accuracy of the histology re-
port, which should not be regarded as a »gold-standard«
unless it is also subjected to audit and quality control.
Quality control of primary screening
Accurate primary screening is central to the cervical
screening process and its quality control is essential. One
of the strengths and weaknesses of cervical cytology
screening is the ease with which the glass slide may be
reviewed, often with the benefit of hindsight, and meth-
ods of quality control should recognise that no test will
be perfect10,11. The most powerful methods of primary
screening quality control involve re-screening the slides
before the reports are issued, thus reducing false nega-
tive rates at the same time as monitoring individual and
laboratory performance. Rapid re-screening of all nega-
tive and inadequate smears (or liquid-based slides) has
been shown to be an effective method of minimising false
negative results12. Rapid pre-screening may be even more
effective13 and both methods are recommended in the
European guidelines. Both are preferable to proportional
re-screening of 10% of negative slides or targeted re-
-screening of supposedly high-risk cases. Where rapid
re-screening or pre-screening is in place, as in the UK, it
may be possible to avoid targeted re-screening altogether.
It should be recognised that either method may fail to de-
tect the very abnormalities that are so easily missed:
slides with small numbers of abnormal cells as well as
pale and small cell dyskaryosis have been shown to be »at
risk« for not being detected at primary screening of con-
ventional smears14,15 and small numbers of abnormal
cells may equally well be missed in liquid-based cyto-
logy16. Sensitivity of primary screening for the individual
and laboratory may be calculated against the final report
after the second screen has taken place and should be
calculated for high-grade cytology alone and for all ab-
normalities. It may be helpful to calculate the »detection
rates« of the final report as part of a performance profile
for each screener17. Performance profiles should be moni-
tored confidentially and sensitively, expectations should
not be too high, and procedures to deal with genuine poor
performance should be agreed in advance.
Pathologists’ and laboratory reporting rates
Apparent sensitivity of primary screening may be in-
fluenced by the accuracy of the final report. A pathologist
with an inappropriately low threshold for reporting atyp-
ical or borderline changes may spuriously reduce the sen-
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Fig 3. Incidence of invasive cervical cancer in England in 2001
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sitivity of the screener. Conversely it is possible for a pa-
thologist to override a screener’s opinion and report a
genuine abnormality as reactive or benign. Pathologists
and laboratory performance may be monitored by com-
paring reporting rates of high-grade and low-grade cytol-
ogy results between observers and between laboratories,
which can improve consistency18. Comparison of high-
-grade reporting rates is used for laboratory quality con-
trol in the NHSCSP and achievable ranges are set each
year based on the 10th and 90th percentiles of national re-
porting rates (www.cancerscreening.nhs.uk/cervical/sta-
tistics). Rates are monitored internally by laboratory
staff, externally by QARCs and are published nationally
each year. While the low limit of high-grade cytology
rates provides a surrogate for sensitivity, the high limit of
low-grade cytology reflects specificity.
Positive predictive value
Positive predictive value (PPV) provides a convenient
measure of accuracy of high-grade cytology reports and
may be regarded as a surrogate for specificity. In the UK
PPV is measured as the percentage of high-grade cytol-
ogy results that are confirmed by at least CIN2 on biopsy
(using cases with known colposcopy outcome as the de-
nominator). Thus PPV may be influenced by the »mov-
ing target« of the histological distinction between CIN1
and CIN2 and by the sensitivity of detection of high-
-grade cytology: high PPVs may be seen with low detec-
tion rates of high-grade cytology. In the UK an achievable
range of PPV is monitored rather than a lower limit only.
Sensitivity of the test is more difficult to measure as
women with negative cytology are seldom referred for
colpsocopy. The rate at which referrals for persistent
low-grade cytology or less are found to have at least CIN3
may be used as a surrogate for sensitivity and provides a
useful balance for PPV (www.cancerscreening.nhs.uk/
cervical/statistics).
Quality control of histology
Because of its central role in the screening process, cy-
tology reporting has been subjected to far more intense
quality control than histology reporting although the lat-
ter forms the basis for decisions about treatment and
management of CIN and invasive cancer. This is stressed
in the European guidelines as well as in the UK pro-
gramme and the NHSCSP provides illustrated guidelines
for reporting cervical biopsies19. It is more difficult to
monitor reporting rates in histology because of the ab-
sence of a population baseline. Nevertheless, quality is
greatly be improved by colposcopic biopsies being re-
ported by specialist teams and slides being reviewed and
presented along with the cytology at multidisciplinary
meetings. Immunohistochemistry is more readily appli-
cable to histology than cytology and difficult distinctions
between low-grade and high-grade CIN may be aug-
mented by Ki67 and P16ink4a staining20. CIN reflects a
continuous spectrum of precancerous changes carrying
an increasing risk of progression so there will always be
inter-observer variation about the dividing lines between
HPV infection and CIN1, between CIN1 and CIN2 and
between CIN2 and CIN3. CIN3 has been shown to be the
most robust of these diagnoses21 and for this reason the
EU guidelines are justified in maintaining the CIN clas-
sification for histological diagnosis although decisions for
treatment are usually made at the level of CIN2.
Principles of laboratory quality control
Quality control should be a continuous process involv-
ing correlation of all parameters and taking account of
the nature of the spectrum of CIN. It requires good re-
cord-keeping and communication – both personal and
electronic – at all stages of the process. Communication
is greatly improved by standardising terminology, which
is naturally more difficult with so many different lan-
guages in use across Europe. The EU guidelines have
solved this problem by recognising that all terminologies
should be locally agreed and should at least be translat-
able into the Bethesda system (Figure 5), which is widely
used throughout the world22. TBS is recommended for
cytology, for which it was originally developed, and the
CIN system is retained for histology.
Testing and Introducing New Technology
The European guidelines are being published at a
time of greatest change since the Pap smear was intro-
duced as a screening test more than 60 years ago. Labo-
ratories, gynaecologists, politicians and women have been
A. Herbert: Quality Control is the Hallmark of Effective Screening, Coll. Antropol. 31 (2007) Suppl. 2: 41–46
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placed under enormous pressure to introduce expensive
new technology including LBC, hrHPV testing and auto-
mated screening. Technology is gradually converting a
simple inexpensive test into a highly complex and much
more costly multi-step process. Whether this new tech-
nology has saved any lives has yet to be determined23.
LBC was introduced throughout the UK after implemen-
tation at pilot sites in Scotland, Wales and three screen-
ing centres in England. The report recommending its im-
plementation made the guarded statement that »overall
sensitivity was at least as good as, and may be better
than, the Pap smear« 24. The main advantage in the UK
was the striking fall in the pilot sites in rates of inade-
quate tests, which were higher with Pap smears com-
pared with elsewhere in the world. There are several ca-
veats to this dramatic decline in rates of inadequate
tests25. Firstly, as NICE pointed out, »there is no way of
verifying that a sufficient number of cervical cells have
been harvested by the smear taker«24. Secondly, all non-
-normal rates are higher in the UK, with 3–5 yearly
screening than in places with annual screening because
there are fewer negative tests. Thirdly, »quality indicator
comments« about poor cellularity, lack of transformation
zone sampling and inflammatory exudate, which are al-
lowed with the Bethesda system22, are not allowed in the
UK. Furthermore, litigation is relatively common in the
UK and cytologists are aware that inadequate smears in-
appropriately reported as negative have been sited as
reasons for »false negative« cytology preceding invasive
cancer26. A multi-centre study has been funded by the
Health Technology Assessment programme to develop
criteria for LBC adequacy appropriate for a 3–5 year
programme. The European guidelines recognise that cri-
teria may be different for organised programmes with re-
stricted intervals and age ranges for screening and, while
regarding LBC as an acceptable method of cell collection,
have not recommended it in place of conventional cytol-
ogy in the absence of a randomised clinical trial to dem-
onstrate its superiority1.
One of the main advantages of LBC is that it facili-
tates hrHPV testing using residual material in the vial.
Some would say that hrHPV testing could replace cytol-
ogy for primary screening27 but this would probably only
be feasible for women over 35 because of high prevalence
of hrHPV in younger women. hrHPV testing is develop-
ing a firmer place in the triage of women with borderline
or atypical cytology almost half of whom may not need
investigation or frequent surveillance28,29. Similarly it is
likely to have an important role in follow-up after treat-
ment of high-grade CIN when the minority of women
with persistent hrHPV could be monitored more closely,
while the majority could be returned to routine screen-
ing. Essentially, hrHPV is the one development that has
the potential to increase specificity of the test by reduc-
ing the number of women investigated for borderline and
ASCUS smears.
HPV vaccination is the one new development that
may fundamentally change cervical cancer screening and
is the subject of a supplement in the European guidelines
and as a separate publication30. Suffice it to say here that
vaccination will not remove the necessity to screen the
current generation of women, including women who are
vaccinated in adult life. Falling rates of abnormal cytol-
ogy in vaccinated women coupled with a false sense of se-
curity might present additional challenges to screening
programmes. There will be even more need to maintain
quality control and high sensitivity of the test – to the ex-
tent that hrHPV testing might be needed as a primary
investigation. There is no doubt that vaccination will
radically affect screening programmes worldwide but lit-
tle is yet known of its likely uptake and even the duration
of protection provided.
Invasive Cancer Audit and its Role
in Quality Control
The ultimate audit of cervical screening lies in moni-
toring invasive cancer incidence and mortality but, as in-
dicated above, these rates should be assessed in relation
to levels of high-grade CIN or CIN3 successfully detected
– both as a measure of effectiveness of screening and of
risk of disease. Invasive cancer rates are likely to be low
in local screening centres and are therefore inappropri-
ate as a local guide of effectiveness. However, audit of
mode of presentation, stage of cancer and screening his-
tory provides a valuable method of monitoring local, re-
gional and national screening programmes. Screening
histories identify areas where screening processes may
be improved – not only with respect to screening and re-
porting the slides. There are multiple factors that may
lead to cancers not being prevented in screened women:
screening may have been intermittent or infrequent, ab-
normalities may have been missed on slides, samples may
have been inadequate, low-grade abnormalities may have
been under-interpreted or not followed up, high-grade ab-
normalities may have been reported but not investigated
and treatment of CIN may have been incomplete or not
followed up31. Isolated reasons or combinations of those
reasons may be implicated in an individual case and bear
witness to the effectiveness of the screening process itself
if correctly and accurately conducted. In well-screened
populations such as the UK it has proved to be easier to
prevent invasive cancer in older age groups8, presumably
because there are more screening opportunities to detect
a lesion that does not progress to invasion until later in
life. Although cancers in young women are more difficult
to prevent, and must have arisen in more aggressive le-
sions, they are frequently detected by positive cytology in
asymptomatic women. These screen-detected cancers are
almost invariably diagnosed at stage 1 (either 1A or 1B)
and present a benefit of screening that provides a benefit
in terms of survival that is not evident from incidence
rates32.
Conclusion
Experience of introducing a highly effective national
screening programme in the UK, in a partially screened
population during a period of increasing risk of disease,
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may provide lessons to other countries introducing na-
tional programmes in the inevitable background of op-
portunistic screening. Auditing screening histories of the
unfortunate few women who develop invasive cancer in
well-screened populations may identify processes that
could be improved. The latest European guidelines for
quality assurance are being published as a time of enor-
mous changes in technology and provide evidence-based
advice to all of us, whether maintaining existing pro-
grammes or starting new ones, to help us navigate those
changes in a cost-effective manner that carries cervical
cancer control forward into the 21st century.
A. Herbert: Quality Control is the Hallmark of Effective Screening, Coll. Antropol. 31 (2007) Suppl. 2: 41–46
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PROBIR RAKA VRATA MATERNICE U UJEDINJENOM KRALJEVSTVU I LABORATORIJSKA
KONTROLA KVALITETE U KONTEKSTU VODI^A EU 2007
S A @ E T A K
Prvi dio ~lanka }e dati osvrt na probir raka vrata maternice u UK za godine prije, za vrijeme i nakon uvo|enja vrlo
uspje{nog organiziranog programa probira raka vrata maternice 1988. g., od kada je stopa pojavnosti invazivnog raka
vrata maternice pala za vi{e od 40%. Organizirani probir je uveden u sjeni oportunisti~kog probira sa lo{om kvalitetom
kontrole u vremenu kada je rizik za bolest rastao, na {to }e ukazati nacionalni registri za rak vrata maternice in situ te
za invazivni karcinom. Program jo{ nailazi na nove izazove, a nedavno je zabilje`io pad u pokrivenosti mla|ih `ena,
uzrok ~ega jo{ mora biti utvr|en. Teku}inska citologija je u procesu uspostave na nacionalnoj razini, ali testiranje na
visokorizi~ne humane papilomaviruse jo{ mora biti uvedeno u program Nacionalnog zdravstvenog sustava (NHS – Na-
tional Health Service). Lekcije iz na{eg iskustva bi mogle biti od zna~aja zemljama koje uvode ili provode organizirane
programe probira pod sli~nim okolnostima. Drugi dio ~lanka }e se baviti laboratorijskom kontrolom kvalitete na na~in
kako se provodi u UK te kako je to preporu~eno u drugom izdanju »Europskog vodi~a za osiguranje kvalitete u probiru
raka vrata maternice«. Ovakvi vodi~i pru`aju preporuke za organiziranje i pra}enje kontrole kvalitete, kao i za uvo-
|enje novih metoda te standardiziranja terminologije, {to je jednako va`no za nove i postoje}e programe. Ispitivanje
invazivnog karcinoma bi moglo ukazati na podru~ja gdje bi postupci mogli biti pobolj{ani bez obzira na vrstu programa,
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